SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Dollar banknote cut into pieces on a yellow background
Mergers & acquisitions
Major Shareholder Opposes Acelyrin’s Merger With Alumis, Prefers Wind-Down
It’s been a fraught road for the proposed merger between Acelyrin and Alumis, with Tang Capital’s Concentra Biosciences in February threatening to upend the deal with a proposed $3-per-share acquisition of Acelyrin.
April 30, 2025
 · 
2 min read
 · 
Tristan Manalac
An obstacle to achieving a goal. Concerns and issues. Break through the refusal barrier. Face problems and challenges.
Prostate cancer
AstraZeneca’s Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails
The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17%.
April 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Tariffs Continue to Dominate Q1 Earnings, AACR Excites Cancer Space, CEO Pay Gaps, More
As Q1 2025 earnings season continues, tariffs remain top of mind for pharma CEOs and investors. Meanwhile, the American Association for Cancer Research’s annual event kicks off this year’s oncology conference season. Plus, will the FDA become politicized under HHS Secretary RFK Jr.?
April 30, 2025
 · 
1 min read
 · 
Heather McKenzie
Gap between rich and poor, income gap, inequity, ruler to measure the distance gap between two piles of gold coins.
C-suite
Top CEO-to-Employee Pay Gaps in 2024
What a CEO makes can be staggering from the seat of a rank-and-file employee, whose pay is typically in the five-to-six digit range.
April 30, 2025
 · 
1 min read
 · 
Annalee Armstrong
Chess made from China and EU, USA flags. Europe Union, USA and China relations
Tariffs
China Still Go-To Source for New Drugs Despite Tariff Minefield
Policy uncertainties are impacting biopharma dealmaking from continent to continent, with companies being asked to walk a tightrope on their relations with China.
April 30, 2025
 · 
10 min read
 · 
Annalee Armstrong
White House seen at night
Earnings
Pfizer CEO Calls Trump’s Pharma National Security Concerns ‘Legitimate’
Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the pharmaceutical industry tariffs, which Trump has threatened, in part as a way to shore up U.S. national security.
April 29, 2025
 · 
3 min read
 · 
Annalee Armstrong
Group Of Employees Being Fired By Their Company.
Layoffs
Octagon Winds Down After Deprioritizing Lead Program
Despite executing perfectly, Octagon confronted a “scientific no-go,” CEO Isaac Stoner said in his LinkedIn post announcing the company’s impending closure.
April 29, 2025
 · 
1 min read
 · 
Angela Gabriel
Artificial skin technology linear icon. Editable stroke. Minimalist medical concept. Medical innovation for tissue regeneration and wound healing. Vector illustration isolated on a white background.
Rare diseases
Abeona Gets FDA Nod for Rare Skin Disease Gene Therapy
The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.
April 29, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Businessman trapped on the road of endless loop
Earnings
Novartis CEO Brushes Off Tariffs but Says Trump Pricing Controls Would Be ‘Devastating’
Vas Narasimhan said on Tuesday that if the U.S. adopts international drug pricing, all companies would have to “relook at their medium- to long-term outlook.”
April 29, 2025
 · 
3 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS